Gene expression analysis in interleukin-12-induced suppression of mouse mammary carcinoma

International Journal of Cancer

Volumn 110, Issue 4, 2004, Pages 570-578

  Shi, Xiaoyan ^a   Liu, Jianguo ^a   Xiang, Zhaoying ^a   Mitsuhashi, Maki ^a   Wu, Rita S ^a   Ma, Xiaojing ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Interferon ; Interleukin 12; Mammary carcinoma; Metastasis; Tumor infiltrating lymphocytes

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOLOGY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOSURVEILLANCE; INTERFERON PRODUCTION; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ESCAPE; TUMOR VASCULARIZATION; UNINDEXED SEQUENCE;

ANIMALS; FEMALE; GENE EXPRESSION PROFILING; INTERLEUKIN-12; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 2542434086     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20145     Document Type: Article

References (44)

1. Browning MJ, Bodmer WF. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 1992;4:613-8.
2. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
3. Naor D. Suppressor cells: permitters and promoters of malignancy? Adv Cancer Res 1979;29:45-125.
4. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells. Science 1993; 259:368-70.
5. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
6. Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999;238:57-78.
7. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-8.
8. Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 2001;941:177-84.
9. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002;99:67-74.
10. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 2000;60:3559-68.
11. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
12. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19:3836-47.
13. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong HS, Kim JA, Nam SJ, Yang JH, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001;12:671-84.
14. Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001;7:895s-901s.
15. Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 1999;5:3983-9.
16. Ansari AA, Mayne AE, Sundstrom JB, Bostik P, Grimm B, Altman JD, Villinger F. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIV-mac251-infected rhesus macaques. J Virol 2002;76:1731-43.
17. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983;33:22-31.
18. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-93.
19. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Research 1992;52:1399-405.
20. Morecki S, Yacovlev L, Slavin S. Effect of indomethacin on tumorigenity and immunity in a maurine model of mammary carcinoma. Int J Cancer 1998;75:894-9
21. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000;7:826-38.
22. Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 2000;49:34-45.
23. Kerbel RS, Hawley RG. Interleukin 12: newest member of the antiangiogenesis club. J Natl Cancer Inst 1995;87:557-9.
24. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 2000;60:3559-68.
25. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 1997;185:817-24.
26. Agarwal VR, Bischoff ED, Hermann T, Lamph WW. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res 2000;60:6033-8.
27. Murata T, Sugatani T, Shimizu K, Manganiello VC, Tagawa T. Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs 2001;12:79-83.
28. Veal E, Groisman R, Eisenstein M, Gill G. The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells. Oncogene 2000;19:2120-8.
29. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint Vis B, Briere F, Bates EE. Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 2002;100:3295-303.
30. Hoover DM, Chertov O, Lubkowski J. The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. J Biol Chem 2001;276:39021-6.
31. Betts CJ, Moggs JG, Caddick HT, Cumberbatch M, Orphanides G, Dearman RJ, Ryan CA, Hulette BC, Frank Gerberick G, Kimber I. Assessment of glycosylation-dependent cell adhesion molecule 1 as a correlate of allergen-stimulated lymph node activation. Toxicology 2003;185:103-17.
32. Nesbit CE, Tersak JM, Grove LE, Drzal A, Choi H, Prochownik EV. Genetic dissection of c-myc apoptotic pathways. Oncogene 2000;19: 3200-12.
33. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983;49:636-49.
34. Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47:487-98.
35. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-63.
36. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 1992;52:6754-60.
37. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Matrix metalloproteinase expression in childhood astrocytomas. Anticancer Res 2000;20: 3287-92.
38. Bodey B, Bodey B, Jr., Groger AM, Siegel SE, Kaiser HE. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 2001;15:175-80.
39. P OC, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:813-20.
40. Claas C, Herrmann K, Matzku S, Moller P, Zoller M. Developmentally regulated expression of metastasis-associated antigens in the rat. Cell Growth Diff 1996;7:663-78.
41. Wurfel J, Rosel M, Seiter S, Claas C, Herlevsen M, Weth R, Zoller M. Metastasis-association of the rat ortholog of the human epithelial glycoprotein antigen EGP314. Oncogene 1999;18:2323-34.
42. Lefebvre L, Viville S, Barton SC, Ishino F, Keverne EB, Surani MA. Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene Mest. Nat Genet 1998;20:163-9.
43. Pedersen IS, Dervan PA, Broderick D, Harrison M, Miller N, Delany E, O'Shea D, Costello P, McGoldrick A, Keating G, Tobin B, Gorey T, et al. Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res 1999;59:5449-51.
44. Pedersen IS, Dervan P, McGoldrick A, Harrison M, Ponchel F, Speirs V, Isaacs JD, Gorey T, McCann A. Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet 2002;11:1449-53.